- Home
- MIST vs CGTX Comparison
MIST vs CGTX Comparison
Compare MIST & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | CGTX |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 79.6M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIST | CGTX |
|---|---|---|
| Price | $1.04 | $0.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $8.00 | $3.33 |
| AVG Volume (30 Days) | ★ 1.7M | 537.6K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,915.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.55 |
| 52 Week High | $3.06 | $3.28 |
Technical Indicators
Market Signals| Indicator | MIST | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 46.96 |
| Support Level | $1.01 | $0.91 |
| Resistance Level | $1.42 | $1.18 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 5.56 | 26.24 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).